Palacaparib

Palacaparib
Clinical data
Other names	AZD-9574
Identifiers
	IUPAC name 6-Fluoro-5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methylpyridine-2-carboxamide;
CAS Number	2756333-39-6;
PubChem CID	162524593;
IUPHAR/BPS	11946;
ChemSpider	115008044;
UNII	9UG32UQW48;
ChEMBL	ChEMBL5095223;
PDB ligand	A1H64 (PDBe, RCSB PDB);
Chemical and physical data
Formula	C21H22F2N6O2
Molar mass	428.444 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NC2=C(C(=C(C=C2)CN3CCN(CC3)C4=C(N=C(C=C4)C(=O)NC)F)F)NC1=O;
	InChI InChI=1S/C21H22F2N6O2/c1-12-20(30)27-18-14(25-12)4-3-13(17(18)22)11-28-7-9-29(10-8-28)16-6-5-15(21(31)24-2)26-19(16)23/h3-6H,7-11H2,1-2H3,(H,24,31)(H,27,30); Key:WXRCLFFPZXJCLS-UHFFFAOYSA-N;

Palacaparib is an investigational new drug that is being evaluated by AstraZeneca for the treatment of prostate cancer.^[1] It is a selective PARP1 inhibitor.^[2]^[3]

References

↑ "Palacaparib". AdisInsight. Springer Nature Switzerland AG. Retrieved 5 July 2026.
↑ Johannes JW, Balazs AY, Barratt D, Bista M, Chuba MD, Cosulich S, et al. (December 2024). "Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor". Journal of Medicinal Chemistry. 67 (24): 21717–21728. doi:10.1021/acs.jmedchem.4c01725. PMID 39655996.
↑ Shkil DO, Chesnokova NA, Ivashchenko AA, Petersen EV, Maximov PY (May 2026). "Structural Determinants of PARP1 Selectivity from Molecular Dynamics Analysis of PARP1 and PARP2 Complexes". Molecules. 31 (10). Basel, Switzerland: 1592. doi:10.3390/molecules31101592. PMC 13210057. PMID 42197145.

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.